|
The Body's Affect on Vitamin C Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about The Body's Affect on Vitamin C conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The Body's Affect on Vitamin C Clinical research trials and The Body's Affect on Vitamin C healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as The Body's Affect on Vitamin C. The Body's Affect on Vitamin C Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a The Body's Affect on Vitamin C clinical trial. Subjects frequently obtain the most expert healthcare possible for their The Body's Affect on Vitamin C condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Body's Affect on Vitamin C  The Body's Affect on Vitamin C
The Body's Affect on Vitamin C
For Condition: Healthy
Status: Recruiting
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ,
Synopsis: Pharmacokinetics is the term used for how the body affects a drug once it is taken. Vitamin C, also known as ascorbic acid, is an essential water soluble vitamin. Meaning, the body does not make Vitamin C it must be taken in through the diet. In this study researchers will attempt to determine how the amount of water consumed affects the level of vitamin C in the blood (specifically the plasma component of the blood). In this study researchers will take 13 subjects and place them on a Vitamin C restricted diet. Vitamin C levels will be measured twice a week on an outpatient basis until all subjects reach a desired low level of Vitamin C (12-15 micromolar plasma ascorbic acid concentration). Subjects will then be admitted and undergo 24 hour blood and urine collection. Following the collection of samples, subjects will then begin to receive Vitamin C orally (by mouth) and intravenously (injected into the vein). The dosage of Vitamin C will gradually increase from 30 mg-2500 mg divided into two daily doses. Blood and urine samples will be collected each time the dose is increased. The study will take approximately 18 weeks after which the subjects will be discharged in healthy condition.
Details: Vitamin C is an essential water soluble vitamin. To date there have been no carefully controlled clinical trials to demonstrate how changes in vitamin C concentration in human plasma vary as a direct function of the amount ingested over a wide range. In this study, we plan to achieve a prescorbutic vitamin C plasma concentration of approximately 12-15 micromolar in thirteen healthy human volunteers and gradually replete these subjects with incremental doses of vitamin C to measure how their plasma concentrations will change as a function of the dose. We will induce vitamin C deficiency in the outpatient setting by having volunteers adhere to a vitamin C restricted diet. As inpatients they will be placed on a more tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma AA concentration of 12-15 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, AA repletion will begin. Escalating doses of AA will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of AA will be determined at each dosage increment. When plasma AA concentration reaches steady state for each dose, subjects will undergo 36 hr plasma AA sampling and a timed 48 hr urine collection. At steady state of each of 4 to 5 doses, an apheresis procedure will be performed for collection of platelets and leukocytes. It is anticipated subjects will be discharged in healthy condition after 18 weeks.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Males and females ages 18-35. Normal volunteers selected from colleges/universities who will: Spend within a fall or spring semester (approximately 12-14 weeks) as an inpatient resident on the endocrine-metabolic ward at NIH. Be willing to adhere an AA restricted diet for 3 weeks prior to their NIH admission as well as for the duration of the time spent in the study as an inpatient at NIH. Have veins adequate for venipuncture and be willing to undergo venipunctures approximately twice per week. Refrain from ingestion of any medication and cigarette smoking. Be able to give informed consent. EXCLUSION CRITERIA: Subject non-compliance with restricted diet. Pregnancy as determined by history, physical exam and urine beta-HCG. History of diabetes mellitus, bleeding disorders, kidney stones, glucose-6-phosphate dehydrogenase deficiency, family history of hemochromatosis/iron overload. Platelet count less than 150,000/ul blood; prothrombin time/partial thromboplastin time (PT/PTT) greater than 1 second above normal upper limit. Positive test for exposure to human immunodeficiency virus. Positive tests for Hepatitis B surface antigen, core antibody or surface antibody.
Total Enrollment: 30
Location and Contact Information:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 920033; 92-DK-0033
Study Start Date: October 25, 1991
Record last reviewed: October 20, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001309
Other Healthy Studies:
1. Evaluation of Neuromuscular Disease
2. Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
3. Endocrine Studies of Healthy Children
4. Study of New Magnetic Resonance Methods
5. Magnetic Resonance Imaging (MRI) of Normal Volunteers
Related Studies:
Other Healthy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
The Body's Affect on Vitamin C
|
|
|
|
|
|
|
|
